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Abstract 
Adams-Oliver syndrome (AOS) is characterized by the association of aplasia cutis 
congenita with terminal transverse limb defects, often accompanied by additional 
cardiovascular or neurological features. Both autosomal dominant and recessive disease 
transmission have been observed, with recent gene discoveries indicating extensive genetic 
heterogeneity. Mutations of the DOCK6 gene were first described in autosomal recessive 
cases of AOS and only five DOCK6-related families have been reported to date. Recently, a 
second type of autosomal recessive AOS has been attributed to EOGT mutations in three 
consanguineous families. Here, we describe the identification of 13 DOCK6 mutations, the 
majority of which are novel, across 10 unrelated individuals from a large cohort comprising 
47 sporadic cases and 31 AOS pedigrees suggestive of autosomal recessive inheritance. 
DOCK6 mutations were strongly associated with structural brain abnormalities, ocular 
anomalies, and intellectual disability, thus suggesting that DOCK6-linked disease represents a 
variant of AOS with a particularly poor prognosis. 
Keywords: Adams-Oliver syndrome, DOCK6, autosomal recessive, brain anomalies, eye 
anomalies. 
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First described in 1945, Adams-Oliver syndrome (AOS) is characterized by the 
combination of terminal transverse limb defects (TTLD) and aplasia cutis congenita (ACC) 
typically located in the midline parietal and/or occipital region of the scalp [Adams and 
Oliver, 1945]. Structures underlying these defects (skull bones, meninges, sinus) may also be 
involved. AOS is often associated with additional congenital vascular anomalies such as cutis 
marmorata telangiectatica congenita (CMTC), reported in around 20% of patients, pulmonary 
hypertension, and lesions of presumed vascular etiology in other organs. Moreover, around 
20% of patients with AOS have congenital cardiac defects including – amongst others – aortic 
valve anomalies, septal defects and tetralogy of Fallot [Snape et al., 2009]. The spectrum of 
congenital anomalies observed in AOS has led to the hypothesis that disturbed vasculogenesis 
may underlie this disorder [Swartz et al., 1999]. AOS is emerging as a very heterogeneous 
disorder, both clinically and genetically. To date, three genes have already been identified as 
causative for the autosomal dominant form, namely ARHGAP31 (MIM *610911; AOS1; 
#100300) [Southgate et al., 2011], RBPJ (MIM *147183; AOS3; #614814) [Hassed et al., 
2012], and NOTCH1 (MIM *190198; AOS5; #616028) [Stittrich et al., 2014]. Two genes, 
DOCK6 (MIM *614194; AOS2; #614219) [Shaheen et al., 2011] and EOGT (MIM *614789; 
AOS4; #615297) [Shaheen et al., 2013], have been reported in pedigrees with autosomal 
recessive transmission of AOS. Each of these genes apparently accounts for only a minor 
proportion of patients. It is therefore likely that further AOS genes will be identified in the 
future. 
Homozygous or compound heterozygous DOCK6 mutations have so far been reported 
in only four inbred Arab families [Shaheen et al., 2011, 2013] and in a single sporadic patient 
[Lehman et al., 2014], respectively. The DOCK6 protein belongs to the conserved dedicator 
of cytokinesis family and has a role in remodeling the actin cytoskeleton by acting as a 
guanine nucleotide exchange factor (GEF) for two members of the Rho GTPase family, 
Cdc42 and Rac1 [Miyamoto et al., 2007]. This regulation of Cdc42 and Rac1 complements 
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the GTPase-activating protein (GAP) activity of the gene product of ARHGAP31 
[Tcherkezian et al., 2006], mutations of which underlie some autosomal dominant cases of 
AOS [Southgate et al., 2011; Isrie et al., 2014], thus pointing at abnormal cytoskeleton 
remodeling as one of the basic pathogenic mechanisms leading to AOS.  
To further understand the role of DOCK6 in the etiology of this disorder and to 
establish possible phenotype correlations, we performed a comprehensive mutation screen of 
this gene in a large and heterogeneous patient cohort. The study cohort consisted of 88 
patients from 78 unrelated families recruited by the partners of the AOS Collaborative Group. 
The presence of both ACC and TTLD in at least one affected family member served as 
minimal clinical inclusion criteria for this study, with the exception of one case that has been 
previously published as a variant of AOS with cognitive impairment, but without scalp defect 
[Brancati et al., 2008]. Additional physical abnormalities were reported in a considerable 
proportion of patients and included cerebral (n=19), ocular (n=13), neurodevelopmental 
(n=25), and cardiac anomalies (n=14). Either sporadic cases of AOS (n=47) or those with a 
pedigree constellation suggestive of autosomal recessive disease transmission (n=31) were 
included. Parental consanguinity and/or the presence of multiple affected children of 
clinically unaffected parents were regarded as possible indicators of autosomal recessive 
inheritance. Families with parent-child transmission of the phenotype suggesting autosomal 
dominant inheritance were excluded. DOCK6 mutation screening was performed by PCR and 
conventional sequencing of all 48 coding exons and flanking intronic regions (Supp. Materials 
and Methods). The study was approved by the institutional review boards of the participating 
centers, University of Magdeburg/Erlangen, Guy’s and St Thomas’ Hospitals London, and 
University of Antwerp. Written informed consent was obtained from the patients and/or the 
parents. Mutations, unclassified variants and phenotype data were submitted to the Leiden 
Open Variation Database (http://databases.lovd.nl/).  
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In this cohort we detected 10 unrelated individuals with biallelic sequence changes in 
DOCK6 that were classified as probable pathogenic mutations. Seven of those patients were 
offspring of consanguineous parents, two originated from non-consanguineous families with 
multiple affected children, and one was a sporadic case with no known parental consanguinity 
(Supp. Figure S1). The overall proportion of DOCK6-related AOS across our complete cohort 
was 13%, with a frequency of 29% (9/31) among the families suggestive of autosomal 
recessive inheritance and 2% (1/47) in sporadic cases with no parental consanguinity. Our 
findings thus underscore the importance of DOCK6 as a gene for autosomal recessive AOS. 
They also suggest that a small proportion of apparently sporadic cases are in fact recessive 
with DOCK6 as the underlying etiology.  
The mutations observed in these 10 families included nonsense (n=1), missense (n=4), 
frameshift (n=4), and splice site mutations (n=3), as well as one larger intragenic deletion-
insertion resulting in deletion of exons 42 to 47. The latter was identified through the failure 
to amplify the terminal exons by PCR and confirmed by focused MLPA and breakpoint 
sequencing (Supp. Figure S1, family 9). Eleven of these 13 mutations were novel and two 
have been previously described as causative of AOS [Shaheen et al., 2011, 2013] (Figure 1A 
and Supp. Table S1). Seven index patients had homozygous mutations consistent with self-
stated parental consanguinity, while the remaining three had compound heterozygous 
changes. Of the four missense mutations observed in this cohort, three were homozygous in 
affected children from consanguineous families (c.3047T>C, p.Leu1016Pro; c.3154G>A, 
p.Glu1052Lys; c.4786C>T, p.Arg1596Trp) and one (c.788T>A, p.Val263Asp) occurred in 
compound heterozygosity with a splice site mutation on the second allele. All four missense 
variations were classified as likely causative mutations on the basis of conservation of the 
affected residue, as assessed by various online prediction tools (Supp. Table S2). Moreover, in 
the consanguineous family harboring the missense mutation p.Leu1016Pro (c.3047T>C, 
family 1), previous homozygosity mapping using a SNP array had been consistent with 
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linkage to the DOCK6 locus in the index patient, demonstrating a 22 Mb stretch of 
autozygosity on chromosome 19 (data not shown). In one pedigree (family 6), segregation of 
compound heterozygosity for the missense mutation p.Val263Asp and a splice site mutation 
on the second allele (c.5939+2T>C) was confirmed in the two affected siblings (Table 1, 
Supp. Figure S1). Of the three splice site mutations observed in this study, one 
(c.4106+5G>T) is outside of the canonical splice site dinucleotide. Unfortunately, no 
appropriate material could be obtained to prove the splicing effect on the mRNA level. 
However, compound heterozygosity for this change and a frameshift mutation on the other 
allele was found to segregate with the phenotype in family 7 (Table 1, Supp. Figure S1). 
Furthermore, splice prediction tools consistently calculated that this change likely abrogated 
splice donor function at this site (Supp. Table S3), thus supporting the likely pathogenic role 
of this variation. To date, six distinct DOCK6 mutations have been reported to underlie the 
AOS type 2  (Figure 1A, Supp. Table S1), with loss of function or expression of the DOCK6 
protein suggested as the basic pathogenic mechanism [Shaheen et al., 2011, 2013; Lehman et 
al., 2014]. Taken together with previous reports, this study demonstrates that DOCK6 
mutations are distributed over the entire gene with no obvious clustering to certain domains of 
the encoded protein (Figure 1A). A deleterious effect on the gene product is plausible for 
most of these changes, as they are predicted to lead to either a truncated protein or nonsense-
mediated mRNA decay. However, the precise functional consequences of the novel missense 
mutations presented here remain to be explored. 
In addition to the pathogenic mutations described above, we also identified 16 
heterozygous DOCK6 sequence variations in our cohort, which remained as unclassified due 
to either uncertain clinical significance or annotation in dbSNP (build 139) as rare variants 
(MAF <0.01) (Supp. Table S4). These variants included predicted amino acid substitutions 
(n=8), synonymous alterations in the coding sequence (n=5), and intronic substitutions within 
20 bp of the splice site (n=3). None of these variations were unambiguously classified as 
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disease-causing by prediction tools. Thirteen unrelated sporadic cases harbored a single 
heterozygous unclassified DOCK6 variant, while two patients were found to have two or 
more variants. Of these, one case had inherited both variants (c.885C>T, p.(=) and 
c.2104G>A, p.Gly702Ser) from the mother on the same allele (data not shown). Another 
patient was found to harbor three unclassified variants (c.885C>T, p.(=); c.1289G>A, 
p.Arg430His; c.1833-19C>G), the segregation of which could not be studied. Notably, this 
patient was previously reported in the literature as a variant subtype of AOS associated with 
cerebral anomalies, seizures and severe MR, but without ACC of the scalp [Brancati et al., 
2008]. While most of these variations are more likely to be non-pathogenic (Supp. Table S5), 
we cannot fully exclude any contribution to the observed phenotype. Our mutation screening 
strategy did not assess mutations of the promoter and intronic changes. We also did not 
systematically screen for larger genomic deletions/duplications. Therefore, it remains possible 
that additional pathogenic variants may have been missed in this cohort and that the given 
figure of the contribution of DOCK6-related disease is somewhat underestimated. However, 
for the DOCK6 mutation-negative patients originating from consanguineous families we can 
state that five had a previous SNP array analysis showing no suggestive stretch of 
homozygosity at the DOCK6 locus (data not shown). In two out of four further subjects who 
had no previous homozygosity mapping, DOCK6 sequencing revealed at least one 
heterozygous SNP, whilst for two cases, sequencing results were uninformative in excluding 
homozygosity at the DOCK6 gene locus. Thus, at least for our consanguineous families we 
can conclude that genes other than DOCK6 are very likely involved in the pathogenesis of 
AOS. Mutations of the EOGT gene may account for part of our DOCK6-negative AOS cases 
[Shaheen et al., 2013]; however mutation screening of this gene was not within the scope of 
this study. It also remains to be seen whether further recessive AOS genes will be identified in 
due course. Moreover, considering the inclusion criteria for this study, it is possible that a 
proportion of our cohort may in fact represent dominant de novo mutations or, in the case of 
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affected siblings with asymptomatic parents, autosomal dominant inheritance with incomplete 
penetrance. 
The main clinical findings of the DOCK6-positive individuals from our cohort are 
summarized in Table 1. Detailed clinical data could be obtained from 10 patients originating 
from eight families. The patients’ ages ranged between one week and 20 years (median 4.3 
years). All except one affected individual from these families had ACC of the scalp and 
TTLD of variable expression; patient 7.2 presented only with mild hypoplasia of toenails 
along with a congenital heart defect, impaired vision and mild cognitive impairment, whereas 
his sister presented with classic AOS features including ACC and TTLD. Across our DOCK6-
positive cohort, the limb defects ranged from minimal hypoplasia of terminal phalanges to 
severe transverse reduction defects (Figure 1B). Notably, aside from ACC typically located 
on the scalp vertex, four patients had additional areas of ACC on the abdomen. Further 
associated anomalies, primarily related to the nervous system, were present in all individuals 
carrying homozygous or compound-heterozygous DOCK6 mutations. Specifically, all patients 
from whom sufficient data could be obtained were reported with developmental delay or 
mental retardation, ranging from mild to severe (Table 1). A broad range of additional 
neurological abnormalities were reported in most cases, including cerebral palsy, spasticity, 
contractures, and epilepsy. Only one patient aged ≥4 years had achieved the ability to walk 
without support. Behavioral abnormalities including autistic behavior or temper tantrums 
were reported in two patients. Brain MRI or CT had been performed for seven patients and 
was abnormal in all cases. The most frequent changes observed on brain imaging included 
ventriculomegaly, periventricular leukomalacia/calcifications, and hypoplasia/atrophy of the 
corpus callosum (Table 1). Images from five affected individuals are exemplarily shown in 
Figure 1C. Patient 4.1 underwent cerebral ultrasonography at 3 months of age which also 
showed ventriculomegaly. A further patient (6.2) was previously reported with ventricular 
dilatation, partial agenesis of the corpus callosum, and periventricular leukomalacia on 
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autopsy [Orstavik et al., 1995]. Where available, measurements of head circumference were 
in the microcephalic range for all eight patients. Ocular anomalies including microphthalmia, 
retinal detachment, and visual impairment were reported in all patients for whom clinical 
information was obtainable. In contrast, cardiac anomalies were observed in only three cases.  
Taken together, the most striking phenotypic attribute of DOCK6-related AOS in the 
presented cohort is the strong association with important neurodevelopmental and ocular 
anomalies. The pattern of neurological impairment and most of the reported morphological 
changes (microcephaly, ventricular dilatation, periventricular calcifications, cortical changes) 
are suggestive of a disruptive vascular pathogenesis rather than a primary maldevelopment of 
the brain. Lesions classified as calcifications according to density analysis, may represent 
primary calcifications but can in fact also have resulted from previous microbleeds. Likewise, 
the main ocular anomalies observed in our DOCK6-positive patients, namely microphthalmia 
and retinal detachment, are compatible with a disruptive vasculogenesis. The high prevalence 
of brain and eye abnormalities as well as the pattern of cerebral and ocular involvement is in 
line with previous case reports (Table 1). However the data on the previously reported 
patients do not provide specific detail to definitely state that brain involvement is a constant 
feature in AOS type 2. While DOCK6 mutations are generally a rare cause of AOS, in our 
cohort they accounted for 8/25 (32%) cases presenting with major neurodevelopmental 
defects and for 9/19 (47%) cases with documented brain abnormalities. Taken together, these 
data suggest that DOCK6 mutations are particularly responsible for a variant of AOS 
characterized by ACC, TTLD plus cerebral and ocular abnormalities. The existence of such a 
variant was previously postulated nearly 20 years ago [Orstavik et al., 1995] and our study 
now confirms that DOCK6 is indeed the gene responsible for the disease in that family 
(family 6). The strong association of DOCK6 mutations with anomalies of the brain and eye 
implies that deleterious effects on angiogenesis caused by DOCK6 deficiency also affect 
development of these particular structures. In their review, Snape et al. concluded that 
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abnormal brain and ocular findings are more common in autosomal recessive AOS [Snape et 
al., 2009]. It is becoming clear that the individuals with DOCK6 mutations account for a 
substantial part for this observation. By contrast, among five patients with EOGT mutations, 
only one patient was reported to have brain anomalies and no abnormal ocular findings were 
reported in any subject [Shaheen et al., 2013]. Nonetheless, across our complete cohort, 
approximately two-thirds of the AOS patients with major neurodevelopmental disorders and 
about half of the cases with structural brain anomalies could not be explained by DOCK6 
mutations, thus suggesting that the association with a neurological phenotype is not specific to 
AOS type 2. 
In summary, by presenting 10 novel families with DOCK6 mutations, we substantially 
expand the clinical and mutational spectrum of AOS type 2. Our findings provide independent 
corroboration that mutations in DOCK6 are responsible for nearly one third of autosomal 
recessively inherited AOS and that this genetic entity also accounts for a minority of sporadic 
cases. AOS type 2 is particularly if not consistently associated with cerebral and ocular 
anomalies in addition to ACC and TTLD. In patients with such a constellation of symptoms 
DOCK6 should therefore be the primary candidate gene for molecular investigation. 
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Figure Legend 
Figure 1: (A) DOCK6 protein with known functional domains and distribution of mutations. 
The protein contains two DOCK homology regions, DHR-1 and DHR-2. DHR-1 spans about 
200 amino acids at the N-terminal end of the protein, whereas DHR-2 is located towards the 
C-terminus and has an approximate length of 500 amino acids [Cote and Vuori, 2002]. All 
currently known mutations are displayed according to their location in the DOCK6 protein. 
Red represents nonsense mutations (n=3), black indicates frameshift mutations (n=5), 
missense mutations are shown in green (n=4), splice site mutations are colored in orange 
(n=4) and the blue line represents one large deletion insertion at the C-terminal end of the 
DOCK6 protein spanning exons 42 to 47. Novel mutations reported in this paper are written 
in italics. (B) Clinical photographs of three DOCK6-positive individuals with AOS from this 
cohort showing areas of alopecia on the vertex resulting from aplasia cutis congenita and 
terminal defects of the digits of varying severity. (C) Brain imaging of AOS patients with 
DOCK6 mutations. Cranial MRI of patient 2.1 at age 1 year: T2-weighted axial section 
showing enlarged lateral ventricles and cerebral atrophy particularly affecting the frontal lobe, 
and contrast enhanced T1-weighted median sagittal section illustrating thin corpus callosum 
and enlarged basal subarachnoid spaces. CT scan of patient 3.1 at age 6 years: Axial sections 
showing ventriculomegaly and periventricular calcifications, and orbital section showing right 
microphthalmia with interocular hyperdensities representing retinal detachment and cystic 
malformation of the anterior chamber. T1-weighted MRI of patient 5.1 at age 3 years: Axial 
sections showing irregularly shaped and slightly dilated lateral ventricles. Axial CT scan 
of patient 6.1 in neonatal period showing ventricular dilatation and multiple periventricular 
calcifications. Brain imaging of patient 10.1: CT scan at age 2 years showing periventricular 
calcifications, and T2-weighted MRI axial section age 3 years showing irregularly shaped, 
slightly enlarged ventricles and mild atrophy of the brain. MRI, magnetic resonance imaging, 
CT, computed tomography. 
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(A) DOCK6 protein with known functional domains and distribution of mutations.  
(B) Clinical photographs of three DOCK6-positive individuals with AOS from this cohort showing areas of 
alopecia on the vertex resulting from aplasia cutis congenita and terminal defects of the digits of varying 
severity.  
(C) Brain imaging of AOS patients with DOCK6 mutations.  
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Table 1: Mutation and phenotype data of DOCK6-positive individuals from this cohort (families 1-10) compared to previously published cases 
(families 11-15). 
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1 1.1 [p.L1016P] + [p.L1016P] F 5y + na + +/+ na na + 
MO, RD, 
VO, ACA 
DD SE high palate - 
2 2.1 [p.T455Sfs*24] + [c.4491+1G>A] M 10y - - + +/+ na 
VD/BA, 
CCH 
+ NS sev ID 
SE, 
CP 
CMTC, 
single umbilical artery, 
cryptorchidism 
- 
3 3.1 [p.Q434Rfs*21] + [p.Q434Rfs*21] M 20y + + + +/+ - VD/BA, PVL + 
MO, RD, 
ACA 
sev ID 
SE, 
CP 
CMTC, 
abdominal skin defect 
- 
4 4.1 [p.R1596W] + [p.R1596W] F 3m + - + +/+ PDA VD/BA + MO na - knee dislocation - 
5 5.1 [p.E1052K] + [p.E1052K] M 9y + + + +/+ - 
VD/BA, 
CCH, PVL 
+ MO, RD mod ID SE cryptorchidism 1 
6 
6.1 [p.V263D] + [c.5939+2T>C] F na - - + +/+ VSD VD/BA, PVL + 
MO, RD, 
VO 
sev ID 
SE, 
CP 
abdominal skin defects, 
absence of right patella 
2 
6.2 [p.V263D] + [c.5939+2T>C]a M 1w† - + + +/+ na 
VD/BA, 
CCH 
na RD na na 
abdominal skin defect, 
patella fixed to skin 
2 
7 
7.1 [p.F635Pfs*32] + [c.4106+5G>T] F 7y - - + +/+ - NS + NS sev ID SE abdominal skin defect - 
7.2 [p.F635Pfs*32] + [c.4106+5G>T] M 8y - + - -/+ TAPVD na na NS mild ID - hypothyroidism - 
8 8.1 [p.E162*] + [p.E162*] F na + na + +/+ na na na na na na  - 
9 9.1 
[c.5235+205_6102-15delins10] + 
[c.5235+205_6102-15delins10] 
F 7y + - + +/+ na PVL na na na na  - 
10 10.1 [p.R841Sfs*6] + [p.R841Sfs*6] F na + - + +/+ na 
VD/BA, 
CCH, PVL 
+ na na SE  - 
11 11.1 [p.T455Sfs*24] + [p.T455Sfs*24] F 11m + na + +/+ - VD/BA, PVL + OA sev ID 
SE, 
CP 
 3 
12 12.1 [p.D416*] + [p.D416*] F 3.5y + na + +/+ - na + - DD na  3 
13 
13.1 [p.R841Sfs*6] + [p.R841Sfs*6] M 1y + na + +/+ AVD VD/BA, PVL na - na na abdominal skin defect 4 
13.2 [p.R841Sfs*6] + [p.R841Sfs*6] F na + na + +/+ na VD/BA, PVL na na na SE gastroschisis 4 
14 14.1 [c.4107-1G>C] + [c.4107-1G>C] F 2y + na + +/+ na PVL, PA na OA na SE  4 
15 15.1 [p.L1064Vfs*60] + [p.E1494*] F 2y - + + +/+ 
TOF, 
PLSVC 
PVL, PE + RD sev ID SE 
placental vasculopathy, 
neonatal thrombocytopenia, 
small bowel infarction 
5 
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a
Genotype was not directly confirmed as patient is deceased but is assumed to be the same as in affected sibling. 
F, female; M, male; y, year(s); m, month(s); w, weeks(s); 
†
, deceased; na, no data available; +, present; -, not present; TTLD, terminal transverse 
limb defects; PDA, patent ductus arteriosus; VSD, ventricular septal defect; TAPVD, total anomalous pulmonary venous connection; AVD, aortic 
valve dysplasia; TOF, tetralogy of Fallot; PLSVC, persistent left superior vena cava; VD/BA, ventricular dilatation / brain atrophy; CCH, corpus 
callosum hypoplasia/atrophy; PVL, periventricular lesions (calcification, gliosis); NS, abnormality present, not further specified; PA, pachygyria; 
PE, porencephaly; MO, microphthalmia; RD, retinal detachment; VO, vitreous opacities/membranes; ACA, anterior chamber abnormality; OA, 
optic atrophy; DD, developmental delay; ID, intellectual disability; sev, severe; mod, moderate; SE, seizures / epilepsy; CP, cerebral palsy / 
spasticity; CMTC, cutis marmorata telangiectatica congenita. References: (1) Prothero et al. (2007); (2) Orstavik et al. (1995); (3) Shaheen et al. 
(2011); (4) Shaheen et al. (2013); (5) Lehman et al. (2014). 
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Supp. Material and Methods 
 
We designed oligonucleotide primers for each of the 48 exons of DOCK6 using the 
Primer3 software version 4.0.0 (http://primer3.ut.ee/) [Untergrasser et al., 2012]. Primer 
sequences and PCR conditions are available upon request. Sequencing was carried out using 
the BigDye Terminator Cycle Sequencing Kit v3.1 on an ABI 3500xl automated capillary 
sequencer (Applied Biosystems, Cheshire, UK). Obtained sequences were compared with the 
reference sequence (NM_020812.3) using the Sequence Pilot software v4.0.1 (JSI Medical 
Systems GmbH, Kippenheim, Germany). Pathogenicity of all observed sequence variants was 
assessed using various online prediction tools. For splice site prediction we utilized the 
following bioinformatic tools: 
- BDGP (Berkeley Drosophila Genome Project) 
last updated 28 July 2014, Human or other, minimum scores for splice sites: 0.1 
http://www.fruitfly.org/seq_tools/splice.html [Reese et al., 1997] 
- NetGene2  
Version 2.4, Human 
http://www.cbs.dtu.dk/services/NetGene2/ [Brunak et al., 1991] 
Missense mutations were rated using the following: 
- PolyPhen-2 (Polymorphism Phenotyping v2) 
Version 2.2.2, NP_065863.2 
http://genetics.bwh.harvard.edu/pph2/ [Adzhubei et al., 2010] 
- SIFT Human Protein (Sorting Intolerant From Tolerant) 
page last modified: August 2011, Ensembl 63, ENSP00000294618 
http://sift.jcvi.org/www/SIFT_enst_submit.html [Ng and Henikoff, 2003] 
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2
Val Phe Ser Leu Val Arg Ala
GTC TTC AGC CTG GTC CGG GCC
Index
Father
Mother
Sister
*
*
*
*
c.3047T>C / p.(Leu1016Pro)
- MutPred (Mutation Prediction) 
last modified 02 Feb 2014, NP_065863.2 
http://mutpred.mutdb.org [Li et al., 2009] 
- GERP (Genomic Evolutionary Rate Profiling) 
hg19, 
http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html [Cooper et al., 2005] 
 
All variants were checked regarding their appearance/frequency in EVS (Exome Variant 
Server, Gene ID: 57572, GRCh37, http://evs.gs.washington.edu/EVS/, [Exome Variant 
Server, 2015]) and TGP (1000 Genomes Project, http://www.1000genomes.org/home, [1000 
Genomes Project Consortium et al., 2010]). Protein conservation across species was checked 
by Standard Protein BLAST (Basic Local Alignment Search Tool, Database: Reference 
proteins (refseq_protein), Algorithm: blastp (protein-protein BLAST), 
http://blast.ncbi.nlm.nih.gov/Blast.cgi, [Altschul et al., 1990]). Segregation of the variants 
across family members was checked if appropriate material was available. Designation of 
mutations follows the guidelines of the Human Genome Variation Society (last modified 
March 2014; http://www.hgvs.org/mutnomen/) [den Dunnen and Antonarakis, 2000] and was 
verified by Mutalyzer (Version 2.0 beta-24; https://mutalyzer.nl/) [Wildeman et al., 2008]. 
A focused MLPA assay including probes for DOCK6 exons 40 through 48 was 
developed (probe sequences available upon request) for copy number determination of the 
terminal DOCK6 exons in a family where PCR amplification of exons 42 to 48 failed in the 
index patient. 
We have established a collection of all mutations and selected unclassified variants in 
the DOCK6 gene (http://databases.lovd.nl/shared/variants/DOCK6) at the Leiden Open 
Variation Database (LOVD, version 3.0) [Fokkema et al., 2011], as well as all available 
phenotype data of patients that were designated as AOS2 both clinically and genotypically 
(http://databases.lovd.nl/shared/individuals/DOCK6). To date, the database contains 17 
different DOCK6 mutations and phenotype data from 18 individuals. 
 
 
 
Supp. Figure S1: Pedigrees and electropherograms of DOCK6–positive AOS patients and 
their families. 
 
Family 1 
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3
Index
Father
Mother
Brother
Arg Arg Arg Gly Pro Gln Asp Arg
CGC CGT CGG GGG CCC CAG GAC CGG
*
*
*
c.1296_1297delinsT / p.(Gln434Argfs*21)
Index
Father
Mother
Ile Gly His +1
ATC GGC CAC g t g a g a g g g g g
*
*
c.4491+1G>A
Family 2 
 
 
 
 
     
 
 
 
 
 
 
 
 
    RNA analysis 
 
   
Family 3 
 
 
 
 
 
 
 
Ex 34         Ex 35
T G T G T C C A A G T T C C C G G A G C
A A C T T T G C C C
Ex 36
Control
Index
Pro Ala Thr Leu Thr Val Thr
CCA GCC ACG CTA ACT GTC ACA
Index
Father
Mother
*
*
c.1362_1365del / p.(Thr455Serfs*24)
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4
Index
Father
Mother
Pro Asp Leu Arg Leu Thr Trp
CCG GAC CTT CGG CTG ACC TGG
*
*
*
c.4786C>T / p.(Arg1596Trp)
Index
Cys Ser His Glu His Tyr Val
TGC AGC CAC GAG CAC TAC GTG
*
c.3154G>A / p.(Glu1052Lys)
Family 4 
 
 
 
 
 
 
Family 5 
 
 
 
 
 
 
 
Family 6 
 
 
 
 
 
 
 
 
 
 
Index
Father
Mother
Arg Ile Leu Val Lys Cys Leu
AGG ATC TTG GTC AAG TGT CTG
*
*
c.788T>A / p.(Val263Asp)
Index
Father
Mother
*
c.5939+2T>C
Cys Lys ... +2
TGC AAG AA g t a g g c g c a a
*
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5
Index
Father
Mother
His His Leu Leu Phe Thr Phe
CAT CAC CTG CTG TTC ACC TTC
c.1902_1905del / p.(Phe635Profs*32)
*
Affected 
Brother
Unaffected 
Brother
Sister
*
*
*
c.4106+5G>T
Index
Father
Mother
Affected 
Brother
Unaffected 
Brother
Sister
Val Asp ...    +5
GTG GAC AA g t a g g t g t g g g
*
*
*
Index
*
Ser Gly Asp Glu Arg Ser Gly
TCT GGA GAC GAG AGG TCC GGC
c.484G>T / p.(Glu162*)
Family 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family 8 
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Intron 41 Insert      Intron 47 Exon 48
A T C T C G A G G G C A G C C A T G G G G C T G C A T T C T T T T T C C A G G A A C T C C T T
c.5235+205_6102-15delinsCATGGGGCTG hom
Control
Index
Father
Mother
Unaffected sister
Unaffected sister
E
x
 4
0
-4
1
E
x
 4
2
-4
3
E
x
 4
4
E
x
 4
5
-4
6
E
x
 4
7
E
x
 4
8
Family 9      MLPA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family 10 
 
 
 
 
 
__________________________________________________________ 
 
Pedigrees representing DOCK6 mutation positive families. Affected individuals are indicated 
by filled symbols. All available genotype data is added and sequence electropherograms are 
shown. Family 2: RNA analysis is additionally displayed. Family 6: in the index patient the 
wild type allele is drastically under-represented regarding the heterozygous c.5939+2T>C 
splice site mutation. We assume this to be caused by a technical artefact due to very poor 
DNA quality. Family 9: MLPA results (multiplex ligation-dependent probe amplification) are 
shown. 
hom, homozygous; het, heterozygous; WT, wild type; ?* patient not listed in table 1 due to 
lack of clinical data and not genetically analyzed due to lack of adequate material. 
Index
*
Tyr Ala Phe Arg Leu Pro Gly
TAC GCC TTT CGC CTT CCT GGC 
c.2520dupT / p.(Arg841Serfs*6)
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Supp. Table S1: Mutations in the DOCK6 gene causing Adams-Oliver syndrome. 
Location Nucleotide Alteration Predicted effect
a Family 
ID 
EVS 
MAF 
(TGP) 
Reference(s) 
Exon 05 c.484G>T p.(Glu162*) 8 - - this paper 
Exon 07 c.788T>A p.(Val263Asp) 6 - - this paper 
Exon 11 c.1245dupT p.(Asp416*) 12 - - Shaheen et al. [2011] 
Exon 12 c.1296_1297delinsT p.(Gln434Argfs*21) 3 - - this paper 
Exon 12 c.1362_1365del p.(Thr455Serfs*24) 2, 11 0.26 % - this paper + Shaheen et al. [2011] 
Exon 17 c.1902_1905del p.(Phe635Profs*32) 7 - - this paper 
Exon 21 c.2520dupT p.(Arg841Serfs*6) 10, 13 - - this paper + Shaheen et al. [2013] 
Exon 25 c.3047T>C p.(Leu1016Pro) 1 - - this paper 
Exon 26 c.3154G>A p.(Glu1052Lys) 5 - - this paper 
Exon 26 c.3190_3191del p.(Leu1064Valfs*60) 15 0.02 % - Lehman et al. [2014] 
Intron 32 c.4106+5G>T r.spl.? p.? 7 - - this paper 
Intron 32 c.4107-1G>C p.Thr1370Metfs*19 14 - - Shaheen et al. [2013] 
Exon 35 c.4480G>T p.(Glu1494*) 15 - - Lehman et al. [2014] 
Intron 35 c.4491+1G>A r.spl.? p.? 2 - - this paper 
Exon 38 c.4786C>T p.(Arg1596Trp) 4 - - this paper 
Intron 41 – 
Intron 47 
c.5235+205_6102-15 
delinsCATGGGGCTG 
p.?
b 
9 - - this paper 
Intron 46 c.5939+2T>C
c 
r.spl.? p.? 6 0.02 % - this paper 
 
a
Italic letters indicate that the effect of splicing mutations was demonstrated on the mRNA level. 
b
MLPA analysis revealed deletion of exons 42 to 47. 
c
This alteration is also listed in dbSNP (rs201387914) with unknown pathogenicity and frequency. Online tools predict destruction of the donor 
splice site.  
Mutation nomenclature refers to GenBank reference sequence NM_020812.3. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. 
EVS (Exome Variant Server): frequency of alterations was calculated according to the total allele count; MAF (minor allele frequency); TGP (1000 
Genomes Project): no entries for these alterations. 
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Supp. Table S2: Prediction of pathogenicity and conservation of DOCK6 missense mutations. 
Nucleotide 
alteration 
Predicted 
effect 
PolyPhen-2 
HumVar 
[sensitivity/specificity] 
SIFT 
[score/median 
information content] 
MutPred GERP BLAST Alignment 
c.788T>A p.V263D 
probably damaging 
(0.998) 
damaging 
0.735 5.05 
Human         263  PPREHFGQRILVKCLSLKFEIEI 
Mmulatta      249  ---EHFGQRILVKCLSLKFEIEI 
Mmusculus     263  PPREHFGQRILVKCLSLKFEIEI 
Trubripes     266  VPKEHCGQRIMVKCLSLKFEIEI 
Drerio        263  VPKEHSGQRIMVKCLSLKFEIEI 
Dmelanogaster 271  IPVEHMGHRIQVNCLQLRLELEV 
Celegans      261  LPEQEETPKLFVKVEKAAADPFF 
Xtropicalis   264  VPKEHFGFRLLVKFLSLKFEIEI 
0.18 / 0.98 0.00 / 2.75 
c.3047T>C p.L1016P 
probably damaging 
(0.977) 
damaging 
0.756 4.84 
Human         1016 LSLVDRGFVFSLVRAHYKQVATR 
Mmulatta      1002 LSLVDRGFVFSLVRAHYKQVATR 
Mmusculus     1080 ----------SLVRAHYKQVATR 
Trubripes     1088 -SLMDRGFVFNLIRSYYKQIANK 
Drerio        1083 -----------LVRSYYKQINNK 
Dmelanogaster 1052 ------GFVFGLIKTYTKVLISK 
Celegans      1027 -----RTFVMKLVHKYLIAFAES 
Xtropicalis   1044 LSLMDRGFVFNLIRSYYKQVMWK 
0.58 / 0.94 0.00 / 2.71 
c.3154G>A p.E1052K 
probably damaging 
(0.999) 
damaging 
0.492 4.81 
Human         1052 RMEFTRILCSHEHYVTLNLPC----CP 
Mmulatta      1038 RMEFTRILCSHEHYVTLNLPC----CP 
Mmusculus     1116 RMDFTRILCSHEHYVTLNLPC----CP 
Trubripes     1124 RMDFIRIVGSHEHYVILNLPC----ST 
Drerio        1119 RMDFIRIICSHEHYVILNLPC----AT 
Dmelanogaster 1088 KIDFLRIVCSHEHFVALNLPFGTSYTM 
Celegans      1063 KIDFVRVVCSYEHYLIVNI-L----SD 
Xtropicalis   1078 ----SHCLGKAGFYFSCSLHC----GH 
0.09 / 0.99 0.00 / 2.71 
c.4786C>T p.R1596W 
probably damaging 
(0.999) 
damaging 
0.715 4.99 
Human         1596 IARGYQGSPDLRLTWLQNMAGKH 
Mmulatta      1583 IARGYQGSPDLRLTWLQNMAGKH 
Mmusculus     1660 IARGYQGSPDLRLTWLQNMAGKH 
Trubripes     1669 IAKGYQNSPDLRLTWL------- 
Drerio        1659 IAKGYQNSPDLRLTWLQNMAGKH 
Dmelanogaster 1618 IAKGYQNNPDLRLTW-------- 
Celegans      1560 --------PDLRITWLLNMAERH 
Xtropicalis   1573 IAKGYQNSPDLRLTWLQNMAAKH 
0.09 / 0.99 0.00 / 2.71 
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Various online prediction tools were used to evaluate mutation effects. PolyPhen-2: score >0.909, probably damaging; score 0.447 – 0.908, 
possibly damaging; score ≤0.446, benign; sensitivity: True Positive Rate, the chance that the mutation is classified as damaging when it is indeed 
damaging; specificity: 1 – False Positive Rate, the chance that the benign mutation is correctly classified as benign [Adzhubei et al., 2013]. SIFT: 
score = normalized probability that the amino acid change is tolerated; ≤0.05, damaging; >0.05, tolerated; median information content: maximum 
4.32, indicates complete conservation at this position; minimum 0.00, indicates a position where all 20 amino acids are tolerated; ideally between 
2.75 and 3.5 [Ng and Henikoff, 2003]. MutPred: general score; ranges between 1.000 (deleterious mutation) and 0.000 (benign). GERP: ranges 
from 6.17 (highly conserved amino acid residue) to -12.3 (not conserved). BLAST Alignment: multiple protein alignment of human DOCK6 and 
its orthologues; numbers indicate position of affected amino acid residue. Black shading indicates identical amino acid residues; grey shading 
indicates similar residues (according to BLOSUM62 matrix). Human: Homo sapiens, ENSP00000294618.6. Mmulatta: Macaca mulatta, 
ENSMMUP00000012229.2. Mmusculus: Mus musculus, ENSMUSP00000034728.7. Trubripes: Takifugu rubripes, ENSTRUP00000027209.1. 
Drerio: Danio rerio, ENSDARP00000077379.4. Dmelanogaster: Drosophila melanogaster, FBpp0077762.3. Celegans: Caenorhabditis elegans, 
F46H5.4.1. Xtropicalis: Xenopus tropicalis, ENSXETP00000036553.2. 
 
 
 
 
 
Supp. Table S3: Splice site prediction c.4106+5G>T. 
  Donor splice site predictions 
 +5 BDGP NetGene2 
Wild type CGCGTGGACAAgtaggtgtgggcaggagggt 0.77 0.881 
Mutant CGCGTGGACAAgtagttgtgggcaggagggt 0.15 0.341 
 
This donor splice site alteration at position +5 in intron 32 was detected in compound heterozygosity with a frameshift mutation in family 7. The 
online tools BDGP (Berkeley Drosophila Genome Project) and NetGene2 predict this nucleotide exchange to impair the regular splice donor site at 
the border between exon 32 and intron 32. The indicated probability scores refer to the authentic splice site. 
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Supp. Table S4: Unclassified variants in the DOCK6 gene. 
Location 
Nucleotide 
Alteration
a Predicted effect
 
dbSNP (139) EVS 
MAF 
(TGP) 
Exon 02 c.100C>G p.(His34Asp) rs201065561 - 0.0004/2 
Exon 09 c.885C>T p.(=) rs146599144 0.46 % 0.0048/24 
Exon 12 c.1289G>A p.(Arg430His) rs143655255  0.30 % 0.0028/14 
Exon 12 c.1358C>T p.(Thr453Met) - - - 
Exon 13 c.1445C>T p.(Pro482Leu) - - - 
Intron 16 c.1833-19C>G r.spl.? p.? rs188183013 0.22 % 0.0028/14 
Exon 19 c.2104G>A p.(Gly702Ser) rs199838752 0.08 % 0.0020/10 
Exon 23 c.2767G>A p.(Val923Ile) rs143194982 0.02 % 0.0002/1 
Exon 30 c.3873C>T p.(=) rs200843111 0.03 % - 
Exon 31 c.3913C>T p.(Arg1305Cys) rs112911897 0.70 % 0.0050/25 
Exon 37 c.4732C>T p.(Leu1578Phe) - - - 
Exon 38 c.4899G>A p.(=) rs72985308 0.20 % 0.0010/5 
Exon 41 c.5229C>A p.(=) rs56243833 0.21 % 0.0026/13 
Exon 44 c.5640C>T p.(=) rs200959822 0.11 % 0.0004/2 
Intron 44 c.5688+9G>C r.spl.? p.? - 0.09 % 0.0002/1 
Intron 45 c.5833-16C>G r.spl.? p.? rs199764395 0.05 % 0.0002/1 
 
Only variants within 20 bp of the exons and MAF ≤ 0.01 were included. All variants show no alteration of splice site prediction in BDGP and 
NetGene2. None of these variants appeared as homozygous in TGP (1000 Genomes Project). The numbering for the nucleotide changes are based 
on cDNA sequence in accordance with the GenBank entry NM_020812.3 (GRCh37). 
a
For cDNA numbering, +1 corresponds to the A of the ATG 
translation initiation codon in the reference sequence. 
EVS: Exome Variant Server, frequency of alterations was calculated according to the total allele count; MAF: minor allele frequency [frequency of 
alternative nucleotide / total allele count of alternative nucleotide]. 
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Supp. Table S5: Prediction of pathogenicity and conservation of DOCK6 unclassified missense variants. 
 
Nucleotide 
alteration 
Predicted 
effect 
PolyPhen-2 
HumVar 
[sensitivity/specificity] 
SIFT 
[Score/Median 
information content] 
MutPred GERP BLAST Alignment 
c.100C>G p.H34D 
benign (0.017) tolerated 
0.155 1.86 
Human         34   KQV---SRERSGSPHSSRR---CSSSLGV 
Mmulatta      20   KQV---SRERSGSPSSSRR---CSSSLGV 
Mmusculus     34   KQV---SRERSGSPHSSRR---SSSSLGV 
Trubripes     32   KQV---SREY-GSPQLSKK[7]VSHVTQL 
Drerio        36   KQV---SREYGSPQMSKKR---AGAHQPV 
Dmelanogaster 33   KNV---SGCHLSKAMDPSL---CGSSISP 
Celegans      35   KHV[7]HRLSEGDNGLDLA---VSMMEKI 
Xtropicalis   34   KQV---AREYGGSPQLSKK---RGGQASV 
0.95 / 0.54 0.34 / 2.77 
c.1289G>A p.R430H 
possibly damaging 
(0.512) 
tolerated 
0.334 3.11 
Human         430  GERRPAWT---DRRRRGPQD---RASSGD 
Mmulatta      416  GERRSAWT---DRRRRGPQ---------- 
Mmusculus     428  --RRPTWA---ERRRRGPQD---RGYSGD 
Trubripes     435  KKGHGTWN---ERKKKG-FE---RMSIAD 
Drerio        431  ----GTWN---ERKKKG-FE---RMSVGE 
Dmelanogaster 431  SLDRKSSTSSFDQLRRKAND[5]------ 
Celegans      423  PMMMSQCT---TASGAVLTT---AGQSQD 
Xtropicalis   431  -ERKGTWN---ERKRKA-FE---RLSVGD 
0.82 / 0.81 0.12 / 2.78 
c.1358C>T p.T453M 
probably damaging 
(0.974) 
damaging 
0.303 4.15 
Human         453  DACSF-SGFRPAT----LTVTNFFKQEA 
Mmulatta      439  DACSF-SGFRPAT----LTVTNFFKQEA 
Mmusculus     451  DACSF-SSFRPAT----LTVTNFFKQEA 
Trubripes     458  DTCNF-ATFRPAT----LTVTNFFKQEG 
Drerio        454  DMCNF-TNFRPAT----LTVTNFFKQEG 
Dmelanogaster 482  DFANVVENFRPIT----ITVPSFFKQEA 
Celegans      465  -------GTSAAT[37]LKFSSFIRQEG 
Xtropicalis   454  ETCGL-HTFRPAT----LTVTNFFKQEG 
0.59 / 0.93 0.00 / 2.78 
c.1445C>T p.P482L 
probably damaging 
(0.991) 
damaging 
0.416 4.42 
Human         482  DLFKFLADMRRPSSLLRRLRPVT 
Mmulatta      468  DLFKFLADMRRPSSLLRRLRPVT 
Mmusculus     480  ----------RPSSLLRRLRPVT 
Trubripes     487  --YKFLADMRRPSSVLRRLRPVT 
Drerio        483  DLYKFLADMRRPSSVLRRLRPVT 
Dmelanogaster 511  DLYKILPELKRP----------- 
Celegans      531  DIYRICSEMRRTNGKVHK-KMFN 
Xtropicalis   482  ---------RRPSTALRRLRPVT 
0.50 / 0.95 0.00 / 2.76 
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Supp. Table S5: Prediction of pathogenicity and conservation of DOCK6 unclassified missense variants. (continued) 
 
Nucleotide 
alteration 
Predicted 
effect 
PolyPhen-2 
HumVar 
[sensitivity/specificity] 
SIFT 
[Score/Median 
information content] 
MutPred GERP 
Alignment 
(numbers indicate position of mutated protein) 
c.2104G>A p.G702S 
benign (0.211) damaging 
0.389 3.62 
Human         702  DVALPGMRWVDGHKGVFSVELTA 
Mmulatta      688  DVALPGMRWVDGHKGVFSVELTA 
Mmusculus     700  DVALPGMRWVDGHKGVFSVELTA 
Trubripes     707  DVQLPGMKWVDNHKGVFSVEVT- 
Drerio        702  DVQLPGMKWVDNHKGVFNVEVKA 
Dmelanogaster 747  NVHLPGIKWLDNHRAVFSINVEA 
Celegans      743  NNALPNLKWVDNHKPIFSCS--- 
Xtropicalis   702  DVQLPGMKWVDNHKPVFSVDLVA 
0.88 / 0.74 0.02 / 2.74 
c.2767G>A p.V923I 
benign (0.029) tolerated 
0.327 3.53 
Human         923  LALQWVVSSSAVREAILQHAWFF 
Mmulatta      909  --LQWVVSSSAVREAILQHAWFF 
Mmusculus     987  LALQWVVSGSAVRELVLQHAWFF 
Trubripes     981  LALQWVVSNSTVREAALQHAWFF 
Drerio        986  LALQWVVSTSTVREASLQQAWFF 
Dmelanogaster 963  LALHWVVASGKAADLAMSNSWFL 
Celegans      943  LLEVWLRARGSLRDVSLVHSWFL 
Xtropicalis   916  LVLQWVVSSAAV----------- 
0.94 / 0.59 0.12 / 2.71 
c.3913C>T p.R1305C 
benign (0.259) damaging 
0.559 2.50 
Human         1305 AFEYKGKKAFERINSLTFKK--SLD 
Mmulatta      1291 AFEYKGKKAFERINSLTFKK--SLD 
Mmusculus     1369 AFEYKGKKAFERINSLTFKK--S-- 
Trubripes     1373 CFEYKGRKALERINSLTFKK--SQD 
Drerio        1368 CFEYKGKKALERINSLTFKK--SQ- 
Dmelanogaster 1329 ---------LKRTNTQSFRKTGSTD 
Celegans      1290 --------ASARRSP--DKT—SL- 
Xtropicalis   1282 CFQYKGKKAFERINSLTFKK--SLD 
0.87 / 0.75 0.00 / 2.71 
c.4732C>T p.L1578F 
possibly damaging 
(0.453) 
damaging 
0.594 4.21 
Human         1578 KMKEHQEDPEMLIDLMYRIARGY 
Mmulatta      1565 ------EDPEMLIDLMYRIARGY 
Mmusculus     1642 KMKEHQEDPEMLMDLMYRIARGY 
Trubripes     1651 KMKEHQQDPEMLIDLMYRIAKGY 
Drerio        1641 KMKEHQQDPEMLIDLMYRIAKGY 
Dmelanogaster 1600 KMKEYQEDPEMLLDLMNRIAKGY 
Celegans      1539 RMREHVNDYEMTIDLMYQLVEGY 
Xtropicalis   1555 KMKEHQQDPEMLIDLMY------ 
0.83 / 0.80 0.02 / 2.71 
 
Legend: see above (Supp. Table S2). 
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